Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
NCT ID: NCT00366834
Last Updated: 2012-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1840 participants
INTERVENTIONAL
2006-07-31
2009-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV on Day 1 + placebo
Dexamethasone intravenous
Ondansetron oral tablets
placebo
casopitant placebo
Single dose oral
ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV + casopitant 150 mg on Day 1
Casopitant (GW679769) oral tablets
Dexamethasone intravenous
Ondansetron oral tablets
3-day oral
ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV + casopitant 150 mg on Day 1 + 50 mg on days 2 \& 3
Casopitant (GW679769) oral tablets
Dexamethasone intravenous
Ondansetron oral tablets
3-day IV/oral
ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV on Day 1 + 90 mg IV casopitant on day 1 and 50 mg oral casopitant on days 2 \& 3
Casopitant (GW679769) oral tablets
Casopitant (GW679769) intravenous
Dexamethasone intravenous
Ondansetron oral tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Casopitant (GW679769) oral tablets
Casopitant (GW679769) intravenous
Dexamethasone intravenous
Ondansetron oral tablets
placebo
casopitant placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject understands the nature and purpose of this study and the study procedures and has signed an informed consent form for this study to indicate this understanding.
* At least 18 years of age.
* Is scheduled to receive their first course of an anthracycline and cyclophosphamide containing moderately emetogenic chemotherapy regimen for the treatment of a solid malignant tumor as outlined in Section 8.1.1.
* Has an ECOG performance status of 0, 1, or 2.
* Hematologic and metabolic status must be adequate for receiving a moderately emetogenic regimen and meet the following criteria:
* Total Neutrophils ≥ 1500/mm³(Standard units : ≥1.5 x 10\^9/L)
* Platelets ≥ 100,000/mm³ (Standard units: ≥100.0 x 10\^9/L)
* Bilirubin ≤ 1.5 x ULN
* Liver enzymes must be below the following limits:
* Without known liver metastases: Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal.
* With known liver metastases: AST and/or ALT ≤ 5.0 x upper limit of normal.
* Is willing and able to complete daily components of the subject diary for each study cycle.
* Women of childbearing potential; must commit to consistent and correct use of an acceptable method of birth control; GSK acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of a physician, are as follows:
1. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal. For purposes of this study, postmenopausal is defined as one year without menses)
2. child-bearing potential: must have a negative serum pregnancy test result or negative urine dipstick pregnancy test within 24 hours prior to the first dose of investigational product of Cycle 1, Day 1 and agrees to one of the following:
* male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject
* oral contraceptives (e.g., oral, injectable, or implantable) with double-barrier method of contraception consisting of spermicide with either condom or diaphragm for a period after the trial to account for potential drug interaction (minimum of six weeks)
* double-barrier method of contraception consisting of spermicide with either condom or diaphragm
* intra-uterine device (IUD) with a documented failure rate of less than 1% per year
* complete abstinence from intercourse for two weeks before exposure to the investigational product throughout the clinical trial, and for a period after the trial to account for elimination of the drug (minimum of three days),
* if subjects indicate they will remain abstinent during the period described above, they must agree to follow GSK guidelines for the consistent and correct use of an acceptable method of birth control should they become sexually active.
Exclusion Criteria
* Is a female subject who is pregnant or lactating.
* Has received radiation therapy to the brain, abdomen, or pelvis in the ten days prior to the first dose of study medication or casopitant investigational product and/or will receive radiation therapy to the brain, abdomen, or the pelvis in the six days following the first dose of study medication (ZOFRAN and dexamethasone) or casopitant investigational product.
* Is scheduled to receive taxane therapy during cycle 1. Note that subjects will be permitted to receive taxane therapy in conjunction with one of the allowed MEC regimens during subsequent cycles.
* Has experienced emesis (i.e., vomiting and/or retching) or clinically significant nausea in the 24 hours preceding the first dose of study medication or casopitant investigational product.
* Has a known central nervous system primary or metastatic malignancy, unless successfully treated with excision or radiation and has been medically stable for at least 1 week prior to receiving the first dose of study medication or casopitant investigational product.
* Has history of documented peptic ulcer disease (via endoscopy or x-ray), active peptic ulcer disease, gastrointestinal obstruction, increased intracranial pressure, hypercalcemia, or any uncontrolled medical condition (other than malignancy) which in the opinion of the Investigator may confound the results of the study, represent another potential etiology for emesis and nausea (other than CINV) or pose an unwarranted risk to the subject.
* Has a known hypersensitivity or contraindication to ZOFRAN, another 5-HT3 receptor antagonist, dexamethasone, or any component of casopitant.
* Has previously received an NK-1 receptor antagonist.
* Received an investigational drug in the previous 30 days or is scheduled to receive any investigational drug other than casopitant during the study period.
* Has taken/received any medication of moderate or high emetogenic potential within the 48 hours prior to the first dose of study medication or casopitant investigational product. Opioid narcotics for cancer pain will be permitted if the subject has been on a stable dose and has not experienced emesis or nausea from the narcotics.
* Has taken/received any medication with known or potential antiemetic activity within the 24-hour period prior to receiving study drug. This includes, but is not limited to:
* 5-HT3 receptor antagonists (e.g., ondansetron, granisetron, dolasetron, tropisetron, ramosetron). Palonestron is not permitted within 7 days prior to administration of investigational product.
* benzamide / benzamide derivatives (e.g., metoclopramide, alizapride)
* benzodiazepines (except if the subject is receiving such medication for sleep or anxiety and has been on a stable dose for at least seven days prior to the first dose of casopitant investigational product; however, lorazepam is prohibited 24 hours prior to receiving study drug regardless of reason for use)
* phenothiazines (e.g., prochlorperazine, promethazine, fluphenazine, perphenazine, thiethylperazine, chlorpromazine)
* butyrophenone (e.g., haloperidol, droperidol)
* corticosteroids (e.g., dexamethasone, methylprednisolone; with the exception of topical steroids for skin disorders, inhaled steroids for respiratory disorders, and prophylactic treatment for taxane therapy during subsequent cycles)
* anticholinergics (e.g., scopolamine, with the exception of inhaled anticholingerics for respiratory disorders e.g., ipratropium bromide)
* antihistamines (e.g., cyclizine, hydroxyzine, diphenhydramine), except for prophylactic use for taxane therapy during cycle 2-4
* domperidone
* cannabinoids
* mirtazpine
* olanzapine
* Has taken/received strong or moderate inhibitors of CYP3A4 and CYP3A5 for a specified period prior to administration of casopitant investigational product (see Section 8.2.1 "Inhibitors of CYP3A4 and CYP3A5")
* Has taken/received inducers of CYP3A4 and CYP3A5 within fourteen days prior to the administration of casopitant investigational product. (see Section 8.2.2 "Inducers of CYP3A4 and CYP3A5")
* Is taking the anti-diabetic agent repaglinide or the diuretic torsemide. Investigators are advised to exercise caution if including patients taking the anti-diabetic agents rosiglitazone or pioglitazone, or antimalarial agents such as chloroquine and amodiaquine, as the metabolite of casopitant is a potential inhibitor of CYP2C8 (See Section 8.2.3 "Substrates for CYP2C8" and Section 8.4 "Necessary Caution with CYP2C8 Substrates").
* Is currently taking or plans to take the any of the following CYP3A4 substrates: astemizole, cisapride, pimozide, terfenadine.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Glendale, Arizona, United States
GSK Investigational Site
Fayetteville, Arkansas, United States
GSK Investigational Site
Hot Springs, Arkansas, United States
GSK Investigational Site
Jonesboro, Arkansas, United States
GSK Investigational Site
Concord, California, United States
GSK Investigational Site
Fountain Valley, California, United States
GSK Investigational Site
Fresno, California, United States
GSK Investigational Site
Greenbrae, California, United States
GSK Investigational Site
La Verne, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Orange, California, United States
GSK Investigational Site
Poway, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Soquel, California, United States
GSK Investigational Site
Norwich, Connecticut, United States
GSK Investigational Site
Washington D.C., District of Columbia, United States
GSK Investigational Site
Boynton Beach, Florida, United States
GSK Investigational Site
Brooksville, Florida, United States
GSK Investigational Site
Fort Lauderdale, Florida, United States
GSK Investigational Site
Fort Lauderdale, Florida, United States
GSK Investigational Site
Inverness, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
New Port Richey, Florida, United States
GSK Investigational Site
Tamarac, Florida, United States
GSK Investigational Site
Tampa, Florida, United States
GSK Investigational Site
West Palm Beach, Florida, United States
GSK Investigational Site
Augusta, Georgia, United States
GSK Investigational Site
Columbus, Georgia, United States
GSK Investigational Site
Lawrenceville, Georgia, United States
GSK Investigational Site
Centralia, Illinois, United States
GSK Investigational Site
Galesburg, Illinois, United States
GSK Investigational Site
Skokie, Illinois, United States
GSK Investigational Site
Evansville, Indiana, United States
GSK Investigational Site
Muncie, Indiana, United States
GSK Investigational Site
Terre Haute, Indiana, United States
GSK Investigational Site
Mason City, Iowa, United States
GSK Investigational Site
Hazard, Kentucky, United States
GSK Investigational Site
Lexington, Kentucky, United States
GSK Investigational Site
Alexandria, Louisiana, United States
GSK Investigational Site
Baton Rouge, Louisiana, United States
GSK Investigational Site
Metairie, Louisiana, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Pittsfield, Massachusetts, United States
GSK Investigational Site
Worcester, Massachusetts, United States
GSK Investigational Site
Clinton Township, Michigan, United States
GSK Investigational Site
Free Soil, Michigan, United States
GSK Investigational Site
Saint Joseph, Michigan, United States
GSK Investigational Site
Troy, Michigan, United States
GSK Investigational Site
Hattiesburg, Mississippi, United States
GSK Investigational Site
Tupelo, Mississippi, United States
GSK Investigational Site
Jefferson City, Missouri, United States
GSK Investigational Site
Rolla, Missouri, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
Billings, Montana, United States
GSK Investigational Site
Great Falls, Montana, United States
GSK Investigational Site
Denville, New Jersey, United States
GSK Investigational Site
Newark, New Jersey, United States
GSK Investigational Site
Somerville, New Jersey, United States
GSK Investigational Site
Sparta, New Jersey, United States
GSK Investigational Site
Albuquerque, New Mexico, United States
GSK Investigational Site
Buffalo, New York, United States
GSK Investigational Site
Durham, North Carolina, United States
GSK Investigational Site
Winston-Salem, North Carolina, United States
GSK Investigational Site
Bismarck, North Dakota, United States
GSK Investigational Site
Akron, Ohio, United States
GSK Investigational Site
Bethlehem, Pennsylvania, United States
GSK Investigational Site
Hershey, Pennsylvania, United States
GSK Investigational Site
Sayre, Pennsylvania, United States
GSK Investigational Site
Mt. Pleasant, South Carolina, United States
GSK Investigational Site
Sumter, South Carolina, United States
GSK Investigational Site
Corpus Christi, Texas, United States
GSK Investigational Site
Corpus Christi, Texas, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Richardson, Texas, United States
GSK Investigational Site
Logan, Utah, United States
GSK Investigational Site
Ogden, Utah, United States
GSK Investigational Site
Burlington, Vermont, United States
GSK Investigational Site
Everett, Washington, United States
GSK Investigational Site
Spokane, Washington, United States
GSK Investigational Site
Tacoma, Washington, United States
GSK Investigational Site
Huntington, West Virginia, United States
GSK Investigational Site
Huntington, West Virginia, United States
GSK Investigational Site
Madison, Wisconsin, United States
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina
GSK Investigational Site
Mendoza, Mendoza Province, Argentina
GSK Investigational Site
Rosario, Santa Fe Province, Argentina
GSK Investigational Site
San Miguel de Tucumán, Tucumán Province, Argentina
GSK Investigational Site
Quilmes, , Argentina
GSK Investigational Site
Salzburg, , Austria
GSK Investigational Site
Sankt Pölten, , Austria
GSK Investigational Site
Vienna, , Austria
GSK Investigational Site
Vienna, , Austria
GSK Investigational Site
Vöcklabruck, , Austria
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Ghent, , Belgium
GSK Investigational Site
Ottignies, , Belgium
GSK Investigational Site
Plovdiv, , Bulgaria
GSK Investigational Site
Shumen, , Bulgaria
GSK Investigational Site
Sofia, , Bulgaria
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Moncton, New Brunswick, Canada
GSK Investigational Site
St. John's, Newfoundland and Labrador, Canada
GSK Investigational Site
Oshawa, Ontario, Canada
GSK Investigational Site
Thunder Bay, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Windsor, Ontario, Canada
GSK Investigational Site
Charlottetown, Prince Edward Island, Canada
GSK Investigational Site
Greenfield Park, Quebec, Canada
GSK Investigational Site
Laval, Quebec, Canada
GSK Investigational Site
Lévis, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Sherbrooke, Quebec, Canada
GSK Investigational Site
Saskatoon, Saskatchewan, Canada
GSK Investigational Site
Zagreb, , Croatia
GSK Investigational Site
Brno, , Czechia
GSK Investigational Site
Chomutov, , Czechia
GSK Investigational Site
Ostrava - Poruba, , Czechia
GSK Investigational Site
Pardubice, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Tábor, , Czechia
GSK Investigational Site
Ústí nad Labem, , Czechia
GSK Investigational Site
Herlev, , Denmark
GSK Investigational Site
Hilleroed, , Denmark
GSK Investigational Site
Tallinn, , Estonia
GSK Investigational Site
Tartu, , Estonia
GSK Investigational Site
Heidelberg, Baden-Wurttemberg, Germany
GSK Investigational Site
Ingolstadt, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Würzburg, Bavaria, Germany
GSK Investigational Site
Hamburg, City state of Hamburg, Germany
GSK Investigational Site
Hamburg, City state of Hamburg, Germany
GSK Investigational Site
Hamburg, City state of Hamburg, Germany
GSK Investigational Site
Kassel, Hesse, Germany
GSK Investigational Site
Würselen, North Rhine-Westphalia, Germany
GSK Investigational Site
Berlin, State of Berlin, Germany
GSK Investigational Site
Berlin, State of Berlin, Germany
GSK Investigational Site
Bad Berka, Thuringia, Germany
GSK Investigational Site
Jena, Thuringia, Germany
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Kavala, , Greece
GSK Investigational Site
Pátrai, , Greece
GSK Investigational Site
Thessaloniki, , Greece
GSK Investigational Site
Hong Kong, , Hong Kong
GSK Investigational Site
Shatin, , Hong Kong
GSK Investigational Site
Tuenmen, , Hong Kong
GSK Investigational Site
Wan Chai, , Hong Kong
GSK Investigational Site
Győr, , Hungary
GSK Investigational Site
Gyula, , Hungary
GSK Investigational Site
Veszprém, , Hungary
GSK Investigational Site
Pune, , India
GSK Investigational Site
Dublin, , Ireland
GSK Investigational Site
Dublin, , Ireland
GSK Investigational Site
Dublin, , Ireland
GSK Investigational Site
Tallaght, Dublin, , Ireland
GSK Investigational Site
Wilton, Cork, , Ireland
GSK Investigational Site
Benevento, Campania, Italy
GSK Investigational Site
Rome, Lazio, Italy
GSK Investigational Site
Genoa, Liguria, Italy
GSK Investigational Site
Sanremo (IM), Liguria, Italy
GSK Investigational Site
Sassari, Sardinia, Italy
GSK Investigational Site
Perugia, Umbria, Italy
GSK Investigational Site
Liepāja, , Latvia
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
Kaunas, , Lithuania
GSK Investigational Site
Klaipėda, , Lithuania
GSK Investigational Site
Vilnius, , Lithuania
GSK Investigational Site
Durango, Durango, Mexico
GSK Investigational Site
Mérida, Yucatán, Mexico
GSK Investigational Site
Lahore, , Pakistan
GSK Investigational Site
Lima, Lima Province, Peru
GSK Investigational Site
Lima, Lima Province, Peru
GSK Investigational Site
Callao, , Peru
GSK Investigational Site
Cebu, , Philippines
GSK Investigational Site
Manila, , Philippines
GSK Investigational Site
Quezon City, , Philippines
GSK Investigational Site
Santa Cruz, Manila, , Philippines
GSK Investigational Site
Krakow, , Poland
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Moscow Region, , Russia
GSK Investigational Site
Saint Petersburg, , Russia
GSK Investigational Site
Samara, , Russia
GSK Investigational Site
Yaroslavl, , Russia
GSK Investigational Site
Bratislava, , Slovakia
GSK Investigational Site
Bratislava, , Slovakia
GSK Investigational Site
Nitra, , Slovakia
GSK Investigational Site
Poprad, , Slovakia
GSK Investigational Site
Žilina, , Slovakia
GSK Investigational Site
Athlone Park, Amanzimtoti, , South Africa
GSK Investigational Site
Bloemfontein, , South Africa
GSK Investigational Site
Observatory, , South Africa
GSK Investigational Site
Panorama, , South Africa
GSK Investigational Site
Parktown, , South Africa
GSK Investigational Site
Saxonwold, Johannesburg, , South Africa
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Donostia / San Sebastian, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Ourense, , Spain
GSK Investigational Site
Santiago de Compostela, , Spain
GSK Investigational Site
Segovia, , Spain
GSK Investigational Site
Zamora, , Spain
GSK Investigational Site
Kaohsiung City, , Taiwan
GSK Investigational Site
Tainan City, , Taiwan
GSK Investigational Site
Taipei, , Taiwan
GSK Investigational Site
Taipei, , Taiwan
GSK Investigational Site
Bangkok, , Thailand
GSK Investigational Site
Chelmsford, Essex, United Kingdom
GSK Investigational Site
Aberdeen, , United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
Maidstone, , United Kingdom
GSK Investigational Site
Nottingham, , United Kingdom
GSK Investigational Site
Shrewsbury, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Herrstedt J, Apornwirat W, Shaharyar A, Aziz Z, Roila F, Van Belle S, Russo MW, Levin J, Ranganathan S, Guckert M, Grunberg SM. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol. 2009 Nov 10;27(32):5363-9. doi: 10.1200/JCO.2009.21.8511. Epub 2009 Oct 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NKV102549
Identifier Type: -
Identifier Source: org_study_id